Are more im­muno-on­col­o­gy buy­outs on the menu at Eli Lil­ly’s ex­ec­u­tive suite?

Flush with cash fol­low­ing the Elan­co spin­off, Eli Lil­ly ex­ecs are talk­ing up the chances of ex­e­cut­ing more near-term buy­outs like their $1.6 bil­lion Ar­mo ac­qui­si­tion ear­li­er this year.

Com­pa­ny CFO Joshua Smi­ley told Reuters that they are steer­ing clear of the Big Phar­ma merg­ers — no sur­prise there — while re­it­er­at­ing the re­cent talk at Lil­ly about ex­e­cut­ing some new ac­qui­si­tions af­ter re­ly­ing large­ly on its in­ter­nal pipeline for new prod­uct de­vel­op­ment. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.